Oral tranexamic acid for the treatment of melasma

It is a prospective, interventional, randomized controlled trial conducted among 260 melasma patients. Patients were divided into two groups consisting of 130 patients each. First group (Group A) was given routine treatment measures and oral Tranexamic Acid while second group (Group B) was treated only with routine topical measures. Capsule Tranexamic Acid was prescribed at a dose of 250 mg twice a day for three months and cases were followed for three months. Response was evaluated on the basis of Melasma Assessment Severity Index (MASI). Mean scores between the two groups were then compared.

[1]  V. Mahajan,et al.  Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study , 2017, Clinical and experimental dermatology.

[2]  A. Ehsani,et al.  Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies , 2017, Dermatologic therapy.

[3]  H. Shimizu.  Disorders of skin color , 2017 .

[4]  T. Thng,et al.  Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. , 2016, Journal of the American Academy of Dermatology.

[5]  R. Fujiwara,et al.  Efficacy and possible mechanisms of topical tranexamic acid in melasma , 2016, Clinical and experimental dermatology.

[6]  J. Na,et al.  Effect of tranexamic acid on melasma: a clinical trial with histological evaluation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  M. Timalsina,et al.  Q-Switched Neodymium-Doped Yttrium Aluminum Garnet laser therapy for pigmented skin lesions: efficacy and safety. , 2013, Kathmandu University medical journal.

[8]  Yi Sun,et al.  Treatment of Melasma With Oral Administration of Tranexamic Acid , 2012, Aesthetic Plastic Surgery.

[9]  A. Manosroi,et al.  Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial , 2012, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[10]  M. Timalsina,et al.  Prevalence of Skin Diseases in Kavre District, Nepal , 2012 .

[11]  J. Halpern,et al.  Interventions for melasma. , 2010, The Cochrane database of systematic reviews.

[12]  P. Grimes.  Management of hyperpigmentation in darker racial ethnic groups. , 2009, Seminars in cutaneous medicine and surgery.

[13]  N. Raza,et al.  Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[14]  S. Walker,et al.  Skin disease is common in rural Nepal: results of a point prevalence study , 2007, The British journal of dermatology.

[15]  Mi-Yeon Kim,et al.  Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[16]  Arthur Rook,et al.  Rook's Textbook of Dermatology , 2004 .

[17]  K. Maeda,et al.  Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. , 1998, Journal of photochemistry and photobiology. B, Biology.

[18]  T. Hamilton,et al.  Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. , 1994, Archives of dermatology.

[19]  K. Goa,et al.  Tranexamic acid: a review of its use in surgery and other indications. , 1999, Drugs.